Evidence map›Paper›PMID 35760992›Full record

ReviewAdvances in experimental medicine and biology2022

Advancing Tumor Microenvironment Research by Combining Organs-on-Chips and Biosensors.

Isabel Calejo, Marcel Alexander Heinrich, Giorgia Zambito, Laura Mezzanotte, Jai Prakash, Liliana Moreira Teixeira

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Isabel CalejoDepartment of Developmental Bioengineering, Technical Medical Centre, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0002-6015-0655
Marcel Alexander HeinrichDepartment of Advanced Organ Bioengineering and Therapeutics, Section: Engineered Therapeutics, Technical Medical Centre, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0003-1392-5697
Giorgia ZambitoDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Laura MezzanotteDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5592-8904
Jai PrakashDepartment of Advanced Organ Bioengineering and Therapeutics, Section: Engineered Therapeutics, Technical Medical Centre, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0003-1050-650X
Liliana Moreira TeixeiraDepartment of Developmental Bioengineering, Technical Medical Centre, University of Twente, Enschede, The Netherlands. l.s.moreirateixeira@utwente.nl.ORCID https://orcid.org/0000-0001-5039-8369

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organs-on-chips are microfluidic tissue-engineered models that offer unprecedented dynamic control over cellular microenvironments, emulating key functional features of organs or tissues. Sensing technologies are increasingly becoming an essential part of such advanced model systems for real-time detection of cellular behavior and systemic-like events. The fast-developing field of organs-on-chips is accelerating the development of biosensors toward easier integration, thus smaller and less invasive, leading to enhanced access and detection of (patho-) physiological biomarkers. The outstanding combination of organs-on-chips and biosensors holds the promise to contribute to more effective treatments, and, importantly, improve the ability to detect and monitor several diseases at an earlier stage, which is particularly relevant for complex diseases such as cancer. Biosensors coupled with organs-on-chips are currently being devised not only to determine therapy effectiveness but also to identify emerging cancer biomarkers and targets. The ever-expanding use of imaging modalities for optical biosensors oriented toward on-chip applications is leading to less intrusive and more reliable detection of events both at the cellular and microenvironment levels. This chapter comprises an overview of hybrid approaches combining organs-on-chips and biosensors, focused on modeling and investigating solid tumors, and, in particular, the tumor microenvironment. Optical imaging modalities, specifically fluorescence and bioluminescence, will be also described, addressing the current limitations and future directions toward an even more seamless integration of these advanced technologies.

Indexed as

Biosensing TechniquesNeoplasmsCellular MicroenvironmentHumansMicrofluidicsTissue EngineeringTumor MicroenvironmentBioluminescenceBiosensorsCancerImagingMicrofluidic systemsOrgans-on-chipsTumor microenvironment

Identifiers

PMID35760992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.